key: cord-0289906-336nzkke
authors: Belda, F.; Mora, O.; Lopez-Martinez, M.; Torres, N.; Vivanco, A.; Marfil, S.; Pradenas, E.; Massanella, M.; Blanco, J.; Christie, R.; Crowley, M.
title: Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration.
date: 2022-04-02
journal: nan
DOI: 10.1101/2022.03.28.22272552
sha: 43208a1581c4e5cac2e0c9be9cf583e940cf4e50
doc_id: 289906
cord_uid: 336nzkke

Seroconversion panels were collected before and after vaccination with three COVID-19 vaccines: two mRNA vaccines (mRNA-1273 and BNT-162b2) and one adenovirus vector vaccine (Ad26.COV2.S). The panels were tested for antibody activity by chemiluminescent immunoassay, ELISA and one was tested in a pseudovirus neutralization assay. Participants positive for anti-SARS-CoV-2 antibodies before vaccination (18.6%) had a higher response to the first vaccine dose than participants who tested negative. For two-dose vaccines, older participants showed a lower response to the first dose than younger participants. All participants showed positive antibody responses after the second vaccine. For the adenovirus vector vaccine, two participants did not generate antibody responses two weeks and two months after vaccination. Three participants were negative at two weeks but positive at two months. Pseudovirus neutralization showed good correlation with antibody activity (correlation coefficient =0.78, p<0.0001). Antibody responses in participants over 45 years old tended to be less robust.

Since the start of the SARS-CoV-2 pandemic, nearly 30 pharmaceutical 44 companies, research institutes and academic laboratories worldwide have been 45 working toward the development of effective vaccines against COVID-19. These efforts 46 have taken various approaches including mRNA, DNA, protein subunits, and 47 attenuated or non-replicating viruses. 65 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The FDA issued an EUA for the mRNA-1273 vaccine for the prevention of 66 COVID-19 in individuals over 18 years of age on December 18, 2020. As with the EUA 67 for BNT-162b2, the EUA for mRNA-1273 was amended in August 2021 to allow the 68 administration of an additional dose to certain immunocompromised individuals. Most SARS-CoV-2 infections induce a response in the adaptive immune system. 85 [9] NAbs that prevent the virus from binding to the host-cell receptor, angiotensin 86 converting enzyme 2 (ACE2) are essential for this immune response. NAbs target the 87 receptor binding domain (RBD) of the viral spike protein and thereby inhibit ACE2 88 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. All samples were stored at -20°C until analyzed. Prior to analysis, samples were 154 thawed at room temperature and mixed by inversion.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint 8

The samples in the seroconversion panels were tested for the presence of anti-SARS-157

CoV-2 antibodies using chemiluminescent immunoassays (CLIA: Liaison SARS-CoV-2 IgG assay, 158

Diasorin, Inc., Saluggia, Italy; EUA approved) and enzyme-linked immunosorbent assays (ELISA: 159

Progenika anti-SARS-CoV-2 IgG Kit, Progenika Biopharma, Derio, Bizkaia, Spain; CE-IVD certified 160 immunoassay). These assays were performed following the directions provided by the 161 manufacturers. The Diasorin assay utilizes antigens to the S1 and S2 spike protein IgG while the 162 Progenika assay utilizes only antigens to S1 IgG. The specific sequences antigens are not 163 disclosed. Since the assays were developed independently, they are assumed to be non-164 identical. Panel 2) showed ten negative and 5 positive anti-SARS-CoV-2 antibody responses in the pre-232 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. showed a negative antibody response at two weeks but a positive response at two months 257 were 30-35 (n=1) and 60-65 (n=2) years old. 258 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Discussion 259

Four seroconversion panels have been created by collecting serum or plasma samples 260 from participants before and after COVID-19 vaccination. Three of the panels were drawn from 261 participants who were administered one of the two-dose mRNA-based vaccines (mRNA-1273 -262 one panel and BNT-162b2 -two panels) and one panel from participants given a single dose of 263 the replication-incompetent adenovirus-based vaccine (Ad26.COV2.S). These panels were 264 tested using CLIA and ELISA technologies. Comparison of the CLIA and ELISA results for the 265 mRNA-1273 panel showed good agreement between these assays. [16] 266 In addition, neutralization assays were conducted in this study and showed 267 congruence between the neutralization assay and the CLIA. Neutralizing activity that blocks 268 viral entry into cell has been shown to be responsible for antibody-mediated prevention of 269 coronavirus infection.

[19] Neutralizing anti-SARS-CoV-2 antibodies have been shown to mainly 270 target the receptor-binding domains on the S1 region of the spike protein.

[20] When 271 immunoassay results correlate with neutralization assays, as in this study, the simpler, less 272 labor-intensive immunoassays may be a useful initial indirect screen for antibody 273 neutralization activity. A similar correlation between immunoassay and neutralization results 274 has been seen in other studies. [21, 22] 275 The results from all the seroconversion panels illustrate several important points 276 regarding antibody responses to vaccination against COVID-19: 1) There is a small but 277 significant fraction (18.6%) of the general population (as measured by the participants in this 278 study) that have been infected with SARS-CoV-2 and have antibodies to the virus prior to 279 vaccination; 2) For the mRNA-based vaccines, the second dose raised anti-SARS-CoV-2 280 antibody levels in participants without a previous SARS-CoV-2 infection to the same levels as 281 those participants who had been infected with SARS-CoV-2 and had antibodies prior to 282 vaccination; 3) Antibody responses tended to be less robust in the participants over 45 years 283 old. 284 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. 

CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res 309 Commun, 2021. 538: p. 187-191. 310 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Ou, X., et al. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.28.22272552 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10. 1101 /2022 

Developmental Status of the Potential Vaccines for the Mitigation of the 289

COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and 290

Differences in IgG antibody responses following BNT162b2 and 292 mRNA-1273 vaccines. bioRxiv

Emergency Use Authorization (EUA) for an unapproved product -review memorandum

COVID-19 Vaccine/BNT-162b2